Therapeutic Treatment of Acute Inflammatory Demyelinating Polyneuropathy: Single Case Report
DOI:
https://doi.org/10.37591/rrjon.v9i1.707Abstract
Background: Guillain-Barré syndrome is an acute inflammatory demyelinating poly-radiculoneuropathy (AIDP) characterized by weakness and a reflexia, typically. The cause of AIDP is still unknown, with suspicions of viral or bacterial infection preceding diagnosis. It can affect people of all ages, gender, or ethnic background, with equal incidence rate in both men and women. The incidence rate for AIDP is rare, affecting 1–2 people in 100,000 annually. Acute Inflammatory Demyelinating Poly-radiculoneuropathy is the most common subtype of Guillain-Barré syndrome. The Result of the case report which shows that at the time of admission, the level of intensity of pain, ADL and balance which measured through NPRS—Pre: 10.5 (P<0.5) and Post: 13 (P<0.5); MBI—Pre: 84(P<0.5) and Post: 100(P<0.5) and BBS—Pre: 32 (P<0.5) and Post: 56 (P<0.5).The investigator Concluded that the present study case report, the opportunity to document outcome of the physiotherapy intervention for AIDP during this episode. Patient with AIDP at the time of discharge achieved all functional capacity of physiotherapy goals and able to return of period functional status, and restore mobility, only mild sensory deficit and minimal weakness. Therefore, the use of functionally based intervention outcome measured during PT (Physical Therapy) management of this strategy for the therapeutic management of AIDP who proved to be clinically more beneficial.
Keywords: Acute Inflammatory Demyelinating Polyneuropathy, (MBI)Modified Barthel Index, (NPRS)Numeric Pain Rating Scale and (BBS)Berg Balance Scale
Cite this Article
Karthikeyan Thangavelu. Therapeutic Treatment of Acute Inflammatory Demyelinating Polyneuropathy: Single Case Report. Research & Reviews A Journal of Neuroscience; 9(1): 13–18p.
Downloads
Published
Issue
Section
License
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
- I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
- I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
- I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
- I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
4. ________________
| We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |
